Baxalta Inc. has agreed to pay Danish biotechnology company Symphogen A/S up to $1.6 billion for the rights to co-develop six experimental cancer drugs, as it nears a multibillion-dollar takeover deal with Shire PLC.
Deerfield, Ill.-based Baxalta is in advanced talks for Dublin-based Shire to take it over in a deal worth up to $ 32.6 billion, according to a person familiar with the matter, who said an agreement could be announced later this week.
Full content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google’s Privacy Class Action Lawsuit Moves Forward After Court Rejects Dismissal Request
Jan 8, 2025 by
CPI
Pilgrim’s Pride Finalizes $100 Million Settlement with Farmers in Wage Suppression Case
Jan 8, 2025 by
CPI
First-of-Its-Kind Ruling: EU Court Ruling Holds European Commission Accountable for GDPR Violation
Jan 8, 2025 by
CPI
EU Rebukes Meta CEO’s Claims of Censorship Under Digital Services Act
Jan 8, 2025 by
CPI
Banco BPM Files Antitrust Complaint Against UniCredit’s Takeover Bid
Jan 8, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand